News

  • 12 September 2016

    (Oxford, UK, 12 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked fourth overall in the 16th annual Sunday Times Hiscox Tech Track 100. Immunocore appears in the league table for the second time, rising up the rank from ninth place in 2015.

  • 7 September 2016

    (Oxford, UK, 07 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, is delighted to announce that it won the “Private UK Life Science Company of the Year” award at the 2016 Biotech and Money Assembly and Awards. Eliot Forster, Chief Executive Officer of Immunocore was also named “UK Life Science CEO of the Year” at the event.  

  • 6 September 2016

    WALTHAM, Mass. and VIENNA, Austria – September 6, 2016 – Arsanis, Inc., a clinical-stage biotechnology company developing targeted monoclonal antibodies (mAbs) for pre-emptive treatment and therapy of serious infectious diseases, today announced two scientific publications in the journals Antimicrobial Agents and Chemotherapy (AAC) and mAbs. Together, these two publications confirm the activity of ASN-1 and ASN-2, the human monoclonal antibodies that comprise Arsanis’ lead clinical candidate, ASN100, targeted against Staphylococcus aureus pneumonia. 

  • 19 August 2016

    August 19, 2016 – The Board of InDex Pharmaceuticals today announced its intention to proceed with an Initial Public Offering of the drug development company on Nasdaq First North during the autumn. A new share issue in order to raise capital for the development of the company’s lead drug candidate – cobitolimod – is planned in connection with the listing.

  • 15 August 2016

    Wilson Therapeutics AB (publ), announces the appointment of Vincent Metzler as Vice President Commercial Planning & Launch Strategy. Dr Metzler will report to CEO Jonas Hansson and will join the company’s management team.